ArticlePloS one2022

Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.

Tomokazu Ohishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.